What is Paediatric Epilepsy Therapeutics Market?
Epilepsy is a chronic neurological disorder characterized by frequent and recurring seizures leading to unusual behavior It can be considered as spectrum disorder due to varied types of seizures, causes, and different degrees of severity. Epilepsy is a condition in which the brain's function is disrupted due to aberrant or excessive electrical discharges from brain cells. Epilepsy is one of the most common diagnoses seen by pediatric neurologists. When antiepileptic drugs fail to relieve seizures adequately in children and adolescents, more invasive therapies such as epilepsy surgery and an implanted device to stimulate the vague nerve should be considered. Increases in online drug purchases are the trend of market growth.
Highlights from Paediatric Epilepsy Therapeutics Market Study
|Unit||Value (USD Million)|
|Key Companies Profiled||Engrail Therapeutics (California), Cerevel Therapeutics (United States), Xenon Pharmaceuticals Inc. (Canada), Amzell (Germany), Eisai (Japan), GlaxoSmithKline (United Kingdom), GW Pharmaceuticals (United Kingdom), Pfizer (United States), W Pharmaceuticals (Belgium) and Abbott Laboratories (United States)|
Paediatric epilepsy Therapeutics is a competitive market due to the presence of a large number of established competitors. The market is highly competitive with a few players occupying the major share. The key players are highly focused on developing and innovating new strategies to maintain their market position and customer base. The companies are also planning strategic activities like partnerships, collaboration, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Paediatric Epilepsy Therapeutics market throughout the forecasted period. Engrail Therapeutics (California), Cerevel Therapeutics (United States), Xenon Pharmaceuticals Inc. (Canada), Amzell (Germany), Eisai (Japan), GlaxoSmithKline (United Kingdom), GW Pharmaceuticals (United Kingdom), Pfizer (United States), W Pharmaceuticals (Belgium) and Abbott Laboratories (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Jazz Pharmaceuticals (Ireland), Novartis (Switzerland) and UCB (Belgium).
Paediatric Epilepsy Therapeutics Market Segmentation:
|Application / End User||Hospitals, Neurology Centers, Home Care Settings and Ambulatory Surgical Centers|
|Disease Type||Benign Rolandic Epilepsy,Childhood Absence Epilepsy,Juvenile Myoclonic Epilepsy,Infantile Spasms,Lennox-Gas taut Syndrome|
|Route of Administration||Oral,Parenteral|
|Therapy Type||Anti-Epileptic Drugs,Dietary Supplements,Surgical Therapies,Others|
On the basis of geography, the market of Paediatric Epilepsy Therapeutics has been segmented into . Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:Growing Funding and Investments for Life Science Research and Increase in online drug purchase
Market Growth Drivers:Increasing Investment by Governments of Various Countries in the Field Of Life Science and the Healthcare Sector and Increasing no of paediatric Epilepsy Therapeutics patient .
Challenges:Major side effects such as liver damage associated with pediatric epilepsy therapeutics
Restraints:Increase in the Amount of Counterfeit Drugs
Opportunities:Increasing developments in patient care through diagnosis and optimal treatment
Key Target Audiencepharmaceutical companies, Government and private laboratories, Research and Development (R&D) companies, Medical research laboratories, Market research and consulting service providers, Government Agencies, End User Industry and Others
Market Leaders & Development StrategiesIn February 2021, The acquisition of the UK heavyweight GW Pharmaceuticals by Jazz Pharmaceuticals has been hailed as a major validation of the medical cannabinoid industryThe deal is the largest to date in the medical cannabinoid field. Jazz’s offer valued GW’s shares nearly 50% higher than their previous day’s close.
In January 2023, Xenon Pharmaceuticals is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy